Present position: Research Director, Molecular Radiopharmacy, INRASTES, NCSR «Demokritos».
Previous Studies and Experience:
Research Activities:
In her present position and for more than 25 years now, Dr. Maina-Nock has been guiding research activities aiming at the development and evaluation of a wide spectrum of radiolabeled peptides for application in targeted diagnostic imaging and radionuclide therapy – “theranostics” – of human tumors.
She has been actively involved in the implementation of national and European scientific projects and research networks related to novel peptide radiopharmaceuticals. She has been responsible for MS and PhD candidates completing their Thesis on related topics.
In addition to drawing public funds for research she has pursued connection with local and European industry and clinical partners. As a result, a solid number of peer-reviewed articles, book chapters (>150) and congress presentations (>300) have been publicly released, while distinct products of this research have been evaluated in well reputed European clinical centers.
In 2013, she and her team in collaboration with Erasmus MC received the prestigious “Marie Curie Award” (https://www.eanm.org/congresses-events/awards-grants/winners/) for their work on the “in situ” stabilization of radiopeptides in vivo by means of co-administration of key-protease inhibitors.
Link to Scopus: https://www.scopus.com/authid/detail.uri?authorId=6701857597#top
Patents:
The research project “Radiolabeled Vectors in Nuclear Oncology” coded Ε12224 with a 5-year duration (2018-2023) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with Cyclotron Rotterdam BV, Erasmus, MC, Rotterdam, The Netherlands. The latter...
The research project “New SST2R-antagonists in the diagnosis of neuroendocrine tumors with PET/CT” coded Ε12452 with a 1-year duration (2020-2022) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Chemistry, ...
The research project “Development of Radiometalated GRPR-Antagonists for Tumor Diagnosis and Therapy” coded Ε11902 with a 3-year duration (2014-2016) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Nuclear Medicine & Radiology ...
The research project “Improved Tumor Targeting with Radiolabeled Peptidomimetics” with a 5-year duration (2018-2023) is coordinated by Dr. B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Ludwig Boltzmann Institute Applied Diagnostics, sponsored by Austrian...
The research project “Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma” coded ERANET TRANSCAN-GRAN-T-MTC (Ε11820) with a 3-year duration (20...
The research project “(Radio)diagnostic - (Radio)therapeutic Peptides and Peptide-like Molecules for Use in Oncology” coded Ε11461 with a 7-year duration (2007-2014) is coordinated by B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Nuclear Me...